RDHL — RedHill Biopharma Ltd.
$0.4232+0.26%
Last close: · regular session
After-hours $0.4151 -1.91% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RDHL in the TickerWise workspace.
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: IL
- Exchange: NASDAQ Global Market
- Employees: 35
- Website: https://www.redhillbio.com
Latest SEC filings for RDHL
Latest RDHL news
- RedHill Biopharma Wins Nasdaq Bid-Price Compliance Extension to April 2027
- Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle
- Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL) Read article
- RDHL 6-K & SEC Filings
- RedHill GAAP EPS of $0.00 Read article
- RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.